Will Differentiated Pricing Spread Across China?
This article was originally published in PharmAsia News
SHANGHAI - China's $124 billion healthcare reform is creating an increased demand for drugs and medical services, with the most significant increases expected for grassroots hospitals and community clinics in rural and less developed urban areas
You may also be interested in...
Are Chinese Price Cut Fears Overstated? Volume Likely To Drive Pharma Industry Growth, Analysts Say
SHANGHAI - As China gets closer to completing its initial $124 billion healthcare reforms next year, analysts are expecting a strong surge in volume-driven growth backed by more provincial drug reimbursement. A top priority of the Chinese reforms is to extend healthcare insurance to 90 percent (1.3 billion) of China's population by the end of 2011, a goal most expect the government to reach
Drug Pricing Reforms Tested In Freewheeling Guangdong Could Be Extended Across China
BEIJING - Pharmaceutical pricing reforms now being tested in the export powerhouse province of Guangdong could be adopted China-wide if they prove successful in balancing the longstanding government goal of making essential drugs affordable for a widening sector of the populace and the newer aim of rewarding innovative drugs with higher price levels
Will China Healthcare Reform Drive Higher Rewards For Innovative Drugs?
BEIJING - China's sweeping healthcare reforms - designed to provide universal coverage for more than 1.3 billion citizens and build or upgrade medical care facilities across the country - are likely to have staggered benefits on varying industries over the next decade